Skip to content

Cannabis-Induced Acute Encephalopathy in a 94-Year-Old Woman Due to Family Administration of Cannabidiol (CBD) Products: A Case Report.

Mohamad K Moussa, Mary Ann Kirkconnell Hall, Joyce Akwe

Cureus April 2023 DOI: 10.7759/cureus.37927 (opens in new tab)

Read Full Text
Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Case study Case report Peer reviewed
Sample size 1
Population A 94-year-old woman
Intervention THC
Duration 5 days until disclosure; recovered to baseline with supportive care
Measures Mini-Cog dementia screening, urine drug screen for tetrahydrocannabinol (THC)
Topics Cannabis CBD
Keywords Cannabidiol CBD Cannabis oil Elderly cannabis use Elderly individuals Encephalopathy Tetrahydrocannabinol THC Unintentional cannabis ingestion
Key findings A 94-year-old woman developed altered mental status, diarrhea, and hallucinations after unknowingly consuming cannabis oil marketed as pure CBD in edible brownies; a urine drug screen verified THC exposure, and she recovered to baseline with supportive care. The authors argue that unregulated CBD products pose risks and that physicians should ask even the oldest patients about cannabis and CBD use.

Abstract

In the United States, cannabis use is rising, including among older adults, as is unintentional ingestion. We describe the case of a 94-year-old woman admitted with altered mental status, diarrhea, and hallucinations. She lived with her family, who had noticed recent confusion with weakness, poor oral intake, and loose bowel movements. In the emergency room, her vital signs revealed mild tachycardia and hypotension. She was lethargic, disoriented, confused, and anxious but could answer simple questions. The attending hospitalist administered the Mini-Cog dementia screening and found that the patient was oriented to herself only and was unable to perform word recall tests or complete a clock drawing. The rest of her physical exam was within normal limits for her age. Despite a workup including urine culture, chest X-ray, and computed tomography scan of her head, no organic source for her mental change was found. After five days of admission, a close relative confessed that they had given the patient cannabis oil (marketed as "pure CBD," i.e., cannabidiol, a nonpsychoactive cannabis derivative widely touted as a remedy for pain, anxiety, and anorexia) in the form of edible brownies to help her with her persistent back pain and poor appetite. We performed a urine drug screen for tetrahydrocannabinol (THC), the psychoactive component of cannabis, which verified cannabis use, as well as exposure to THC. The patient recovered to baseline with supportive care. Currently, there is no governing body or framework for the regulation of cannabis products in the United States. Nonprescription CBD products are not regulated by the US Food and Drug Administration, and these products are not tested for safety, efficacy, or quality. Some producers voluntarily conduct such testing, but there is no regulatory oversight, and consumers may be unaware of the need for testing and/or which testing bodies are credible. Given the rapidly increasing proportion of older adults who are cannabis users, physicians should inquire about outpatient use of cannabis in general and CBD in particular during discussions with patients, even the most elderly.

Comparable studies

Other case reports and case series on CBD, most cited first.

Study Year Design Participants
Cannabis‐induced Koro in Americans American men aged 22-26 with years of cannabis experience who reported negative... 2001 Case series n = 3
Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: A case series. Inpatients diagnosed with a psychotic disorder and treatment-resistant cannabis use... 2018 Case series n = 7

Citations in the library

Cites 4

Related reading

Explore topics

Cannabis CBD Anxiety